Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Miracle cures are few and far between. The best one can hope for is partial relief. So it is with Sanofi ...

Sanofi (NASDAQ:SNY) shares gained on Friday after the French pharma giant exceeded analysts' estimates with its Q3 thanks mainly to earlier-than-anticipated vaccine sales and a 22% YoY rise in ...

Our settings allow us to accept postcards and telegrams. … French unions have called on workers at Sanofi to strike starting on Thursday to protest a planned sale of the company’s consumer ...

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...

Sanofi pitched today’s announcement in the context of its move last month to pay Orano Med and its partner RadioMedix 100 million euros upfront and commit up to 220 million euros in sales ...

Sanofi SAN-1.01%decrease; red down pointing triangle moved ahead with a plan to sell a controlling stake in its consumer-healthcare unit Opella to Clayton Dubilier & Rice, entering exclusive talks ...

PARIS (Reuters) -Sanofi on Sunday reached an agreement on terms to sell a controlling stake in its consumer health unit Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R), French ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Sanofi has struck a deal in the hotly competitive radiopharmaceuticals sector, buying a $300mn stake in a ...

PAI Partners has submitted an improved offer for Sanofi’s consumer health business, according to people familiar with the matter, an unexpected twist in one of the biggest deals in Europe this year.

Sanofi’s shares traded 0.2% lower on Monday morning in Paris. The stock has risen about 2% over the past 12 months. Despite the commitments it faces in France, CD&R has been drawn to the Sanofi ...

Sanofi entered into exclusive talks to sell a controlling stake in its consumer-healthcare business Opella to Clayton Dubilier & Rice in a deal that values the business as a whole at 16 billion ...